Soligenix Halts FLASH2 Trial for HyBryte, Shifts Focus to Behçet's Disease and Strategic Options
Event summary
- Soligenix halted its Phase 3 FLASH2 trial for HyBryte (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL) due to futility.
- The company reported a net loss of $2.8 million for Q1 2026, down from $3.0 million in Q1 2025, with $6.0 million in cash as of March 31, 2026.
- Soligenix is exploring strategic options, including mergers, acquisitions, and advancing SGX945 (dusquetide) for Behçet's Disease.
- SGX945 received orphan drug designation from EMA and Promising Innovative Medicine (PIM) designation from MHRA.
- SGX302 (synthetic hypericin) gel showed promising results in a Phase 2a trial for mild-to-moderate psoriasis.
The big picture
Soligenix's decision to halt the FLASH2 trial marks a significant shift in its strategic focus, as it pivots towards other pipeline assets like SGX945 and SGX302. The company's ability to navigate this transition will be critical, given its limited cash runway and the competitive landscape in rare disease therapeutics. The broader biotech sector continues to face challenges in securing funding and regulatory approvals, making Soligenix's strategic moves a key area of interest for investors and analysts.
What we're watching
- Pipeline Pivot
- Whether Soligenix can successfully shift focus to SGX945 for Behçet's Disease and SGX302 for psoriasis after the FLASH2 setback.
- Financial Sustainability
- The pace at which Soligenix can secure additional funding or strategic partnerships to extend its cash runway beyond Q2 2027.
- Regulatory Engagement
- How discussions with EMA and FDA on potential subsets of patients who may benefit from HyBryte will impact future development strategies.
Related topics